Founders Capital Management (Texas)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Founders Capital Management (Texas)’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$5K	–	328
2019 Q3	$5K	Hold	1,000	–	–	﹤0.01%	300
2019 Q2	$6K	Hold	1,000	–	–	0.01%	294
2019 Q1	$5K	Hold	1,000	–	–	﹤0.01%	306
2018 Q4	$4K	Hold	1,000	–	–	﹤0.01%	306
2018 Q3	$6K	Hold	1,000	–	–	﹤0.01%	276
2018 Q2	$8K	Hold	1,000	–	–	0.01%	265
2018 Q1	$7K	Hold	1,000	–	–	0.01%	309
2017 Q4	$6K	Buy	+1,000	New	+$6.08K	0.01%	310

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Founders Capital Management (Texas)'s PGNX Position: Q4 2019 in Review

Founders Capital Management (Texas) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Founders Capital Management (Texas) first reported a position in PGNX in Q4 2017 and held it in 8 quarters. The position peaked at $8K in Q2 2018. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

Founders Capital Management (Texas) reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
Founders Capital Management (Texas) sold 1,000 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $5K.
Founders Capital Management (Texas) first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 8 quarters.
Founders Capital Management (Texas)'s Progenics Pharmaceuticals Inc position peaked at $8K in Q2 2018.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Founders Capital Management (Texas)'s 13F filing for Q4 2019, filed 24 Jan 2020.